Mersana Therapeutics (MRSN) Receives a Buy from TD Cowen
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
Hosted on MSN8d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation
Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
Nasdaq17d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation
The firm decreased its portfolio allocation in MRSN by 0.59 ... companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors ...
ETF Daily News21d
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Target Price from Analysts
The average 1 year target price among brokers that have covered the stock in the last year is $5.57. MRSN has been the topic of a number of recent research reports. Wedbush reaffirmed an ...